Inclusion Criteria:

1. Male or female ≥ 14 - 90 years of age. If female of child-bearing potential and
outside of the window of 10 days since the first day of the last menstrual period, a
negative pregnancy test is required.

2. Presence of somatostatin receptor positive tumour(s) (either histologically or
Octreoscan image proven), with at least 1 tumour site reliably evaluable by CT or MRI
of at least 1.5 cm (smallest dimension) with respect to RECIST criteria (the target
lesion).

3. Presence of somatostatin receptors on (at least) the target lesion demonstrated by
uptake of OctreoScan® at least equal to liver uptake within 26 weeks of enrollment.

4. Life expectancy greater than 12 weeks from enrollment.

5. Serum creatinine ≤ 150 µmol/L, and a measured GFR using plasma clearance of ≥50
mL/min measured within 2 weeks of enrollment.

Exclusion Criteria:

1. Potential for surgery with curative intent. Local surgery for symptomatic relief
permitted as long as target lesion unaffected.

2. Surgery, radiation therapy, radioisotope therapy, change in Sandostatin LAR therapy
dosage, cytotoxic chemotherapy, embolization or other investigative therapy
(interferons, mTOR inhibitors) within 12 weeks of enrollment. Localized external beam
irradiation permitted as long as target lesion unaffected.

3. Known brain metastases unless these metastases have been treated and stabilized
(confirmed by CT) for ≥ 6 months prior to enrollment.

4. Uncontrolled diabetes mellitus defined as fasting glucose ≥ 3X the upper limit of
normal within 12 weeks of enrollment.

5. Another significant medical, psychiatric or surgical condition uncontrolled by
treatment, which may interfere with completion or conduct of the study (such as
urinary incontinence, co-existing malignancies).